GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.20
-0.07 (-0.96%)
▼
5d:
+0.42%
30d:
-1.64%
90d:
-12.3%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 27, 2026
12d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GRFS appears deeply undervalued. Market expects -6.1% annual earnings decline despite 44% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: GRFS appears deeply undervalued. Market expects -6.1% annual earnings decline despite 44% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.48
31.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.20, which is considered oversold relative to its 30-day fair value range of $7.19 to $7.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.0) compared to its historical average (6.0). Remarkably, the market is currently pricing in an annual earnings decline of 6.1% over the next few years. This pessimistic expectation contrasts with the company's recent 43.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a strong downtrend. Immediate support is located at $6.96, while resistance sits at $7.43.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.87 (+50.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GRFS is in a strong downtrend. Immediate support is located at $6.96, while resistance sits at $7.43.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $10.87 (+50.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.19 -
$7.56
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 50.9% below Wall St target ($10.87)
Trading Range Analysis
30-Day Trading Range
$7.19 -
$7.56
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.96
Resistance Level
$7.43
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.98
Wall Street Target
$10.87
(+50.9%)
Revenue Growth (YoY)
-4.8%
Earnings Growth (YoY)
43.5%
Profit Margin
5.6%
Valuation Discount vs History
-6.1% cheaper
PE vs Historical
5.0 vs 6.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.1%
(market-implied from PE analysis)
1-Year Target
$6.76
(-6%)
2-Year Target
$6.35
(-12%)
3-Year Target
$5.96
(-17%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$7.18
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 36.0%)
$79.19
(+1000%)
Base:
(SPY PE: 5.0, Growth: 36.0%)
$18.12
(+152%)
Bear:
(PE: 4.2, Growth: 36.0%)
$15.41
(+114%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 10.54 | Current EPS (TTM): $0.69
Bull Case
$15.99
(+122%)
Analyst growth 100.0%, PE expands to 11.6
Base Case
$14.54
(+102%)
Market implied 100.0%, PE stable at 10.5
Bear Case
$4.94
(-31%)
Severe decline -20.0%, PE contracts to 9.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.0 to 6.0
Stabilization Target:
$8.67
(+20.4%)
PE Expansion Potential:
+20.4%
Share & Embed Analysis
Last updated: July 14, 2026 2:08 AM ET
Data refreshes hourly during market hours. Next update: 3:08 AM
Data refreshes hourly during market hours. Next update: 3:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1240 | 58 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 64 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$263 | 59 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$223 | 59 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$356 | 56 HOLD |
